Genetic engineering strategies for cell-based therapy: viral, non-viral, and precision genome editing technologies
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e327Keywords:
Chimeric antigen receptor, Genome editing, Cell-based therapy, In vivo CAR-T therapyAbstract
Objective: To review the existing genetic engineering strategies commonly used for generating chimeric antigen receptor (CAR)-T cell therapy. Methods: This article provides a comprehensive literature review and compares different approaches on viral, non-viral and precision genome editing technologies, aiming to provide an overview and guidelines for methods selection during clinical CAR-T cell manufacturing. Results: CAR-T cell therapy has revolutionized cancer treatment for hematological malignancies. The manufacturing of CAR-T cell therapy relies on the genetic modification of T cells to achieve ectopic CAR gene expression. Depending on the evolving CAR designs, viral, non-viral, and genome editing platforms are used for optimal CAR expression, which could determine the clinical efficacy and safety profiles of these products. Efforts have been ongoing to empower CAR-T cell efficacy while minimizing toxicity over the past decades. Conclusion: Successful CAR-T cell therapy depends on rational platform selection and optimization of gene delivery methods based on clinical needs and context.
References
1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-98. https://doi.org/10.1158/2159-8290.CD-12-0548 DOI: https://doi.org/10.1158/2159-8290.CD-12-0548
2. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-41. https://doi.org/10.1038/s41375-018-0106-0 DOI: https://doi.org/10.1038/s41375-018-0106-0
3. Jaballah SA, Ali LM, Jehad MA, Akhlaq S, Rizvi TA, Mustafa F. Retroviral vector technology for gene therapy: history, current landscape, and future prospects. J Mol Biol. 2025;437(24):169473. https://doi.org/10.1016/j.jmb.2025.169473 DOI: https://doi.org/10.1016/j.jmb.2025.169473
4. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358-78. https://doi.org/10.1038/s41573-019-0012-9 DOI: https://doi.org/10.1038/s41573-019-0012-9
5. Swift S, Lorens J, Achacoso P, Nolan GP. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol. 2001;Chapter 10:Unit 10.7C. https://doi.org/10.1002/0471142735.im1017cs31 DOI: https://doi.org/10.1002/0471142735.im1017cs31
6. Han J, Bai H, Li F, Zhang Y, Zhou Q, Li W. Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery. Nat Commun. 2025;16(1):9157. https://doi.org/10.1038/s41467-025-64181-9 DOI: https://doi.org/10.1038/s41467-025-64181-9
7. Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next-generation CAR T-cell immunotherapy. Nanoscale Horiz. 2026;11(1):22-36. https://doi.org/10.1039/D5NH00432B DOI: https://doi.org/10.1039/D5NH00432B
8. Tkachenko E, Ponomareva N, Evmenov K, Kachanov A, Brezgin S, Kostyusheva A, et al. CAR therapies: ex vivo and in vivo potential of exosomes and biomimetic nanoparticles. Cancers (Basel). 2025;17(23):3766. https://doi.org/10.3390/cancers17233766 DOI: https://doi.org/10.3390/cancers17233766
9. Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2011;11(1):11-27. https://doi.org/10.2174/156652311794520111 DOI: https://doi.org/10.2174/156652311794520111
10. Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773-82. https://doi.org/10.1534/genetics.111.131433 DOI: https://doi.org/10.1534/genetics.111.131433
11. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824-44. https://doi.org/10.1038/s41587-020-0561-9 DOI: https://doi.org/10.1038/s41587-020-0561-9
12. Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, et al. TET2 guards against unchecked BATF3-induced CAR T-cell expansion. Nature. 2023;615(7951):315-22. https://doi.org/10.1038/s41586-022-05692-z DOI: https://doi.org/10.1038/s41586-022-05692-z
13. Harrison S, Ho PJ, Lim SL, Talam S, Pahl H, Dingar D, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146(Suppl 2):LBA-1. https://doi.org/10.1182/blood-2025-LBA-1 DOI: https://doi.org/10.1182/blood-2025-LBA-1
14. Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393(15):1542-4. https://doi.org/10.1056/NEJMc2509522 DOI: https://doi.org/10.1056/NEJMc2509522
15. Karimi A, Kazemi-Harikandei SZ, Alilou S, Salabat D, Pourfaraji SM, Shirmard FO, et al. Improving CAR T-cell therapy against malignancies through gene knock-down/out strategies: a systematic review. Cancer Cell Int. 2025;26(1):8. https://doi.org/10.1186/s12935-025-04090-5 DOI: https://doi.org/10.1186/s12935-025-04090-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Wing Keung Chan, Marcos de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
